Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

Stock Information for Quanterix Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quanterix Corporation

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Quanterix to Participate in Upcoming Investor Conferences
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.